Dangerous MAP Ads Threaten Public Health
March 26, 2004 Volume 6 / Number 12 Dear Colleague: On February 20, 2004, the Food and Drug Administration (FDA) announced it would delay for 90 days its decision to approve over-the-counter (OTC) status of the morning-after pill (MAP). The FDA said it needed more